bluebird bio’s (BLUE) Neutral Rating Reiterated at Cantor Fitzgerald

bluebird bio (NASDAQ:BLUE)‘s stock had its “neutral” rating reissued by stock analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

BLUE has been the subject of several other reports. JPMorgan Chase & Co. cut bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday, August 15th. Bank of America cut their price objective on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Barclays decreased their target price on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a report on Thursday, August 15th. Robert W. Baird cut their price target on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, August 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.74.

bluebird bio Trading Up 0.7 %

Shares of BLUE opened at $0.61 on Monday. bluebird bio has a 12 month low of $0.52 and a 12 month high of $5.53. The firm’s 50 day moving average is $0.89 and its 200-day moving average is $1.02. The stock has a market capitalization of $66.70 million, a PE ratio of -0.82 and a beta of 0.75.

Institutional Trading of bluebird bio

A number of hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in shares of bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after acquiring an additional 1,013,144 shares during the last quarter. Allegheny Financial Group LTD bought a new position in bluebird bio in the second quarter valued at about $25,000. Rhumbline Advisers boosted its stake in shares of bluebird bio by 25.4% during the second quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 59,219 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company’s stock worth $675,000 after purchasing an additional 111,574 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of bluebird bio during the first quarter worth about $52,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.